Needed in MS: Evidence, not evidence

Neurology

Volumn 59, Issue 10, 2002, Pages 1482-1483

  Kieburtz, Karl ^a   McDermott, Michael ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NEUTRALIZING ANTIBODY;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MARKETING; DRUG SYNTHESIS; DRUG TOLERANCE; EDITORIAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; INJECTION SITE; LEUKOCYTE COUNT; MEDICAL LITERATURE; METHODOLOGY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037180405     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.10.1482     Document Type: Editorial

References (2)

1. Clanet M, Radue EW, Kappos L, et al. A randomized double-blind, dose-comparison study of weekly interferon beta-1a (Avonex) in relapsing MS. Neurology 2002;59:1496-1507.
2. Panitch H, Goodin DS, Francis G, Chang P, et al. Randomized comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 2002;59:1507-1517.